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Abstract 
 
Administration of anti-inflammatory cytokines is a common therapeutic strategy in 
chronic inflammatory diseases. Gene therapy is an efficient method for delivering 
therapeutic molecules to target cells. Expression of the cell adhesion molecule E-
selectin, which is expressed in the early stages of inflammation, is controlled by pro-
inflammatory cytokines, making its promoter a good candidate for the design of 
inflammation-regulated gene therapy vectors. This study describes an E-selectin 
promoter (ESELp)-based lentiviral vector that drives localized transgene expression 
during inflammation. Mouse matrigel plug assays with ESELp-transduced endothelial 
cells showed that systemic LPS administration selectively induces ESELp-controlled 
luciferase expression in vivo. Inflammation-specific induction was confirmed in a 
mouse model of arthritis, showing that this lentiviral vector is repeatedly induced early 
in acute inflammation episodes and is down-regulated during remission. Moreover, the 
local acute inflammatory response in this animal model was efficiently blocked by 
expression of the anti-inflammatory cytokine IL-10 driven by our lentiviral vector 
system. This inflammation-regulated expression system has potential application in the 
design of new strategies for the local treatment of chronic inflammatory diseases such 
as cardiovascular and autoimmune diseases. 
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Introduction 
 
Chronic inflammatory diseases are characterized by episodes of relapse and remission 
that often involve superposition of acute inflammation on top of the inflammation 
already present. Altering the cytokine network is a common therapeutic strategy in 
inflammatory diseases. Therapies based on natural cytokines are very promising as they 
are more effective, better tolerated, and more specific than pharmacological treatments 
[1]. One way to regulate inflammatory cytokine activity is to administer anti-
inflammatory cytokines, such as interleukin-10 (IL10). Compared with other anti-
inflammatory molecules such as IL-4 or IL13, IL10 has a broader spectrum of anti-
inflammatory activities, inhibiting the production of several pro-inflammatory cytokines 
(e.g. IL1, IL2, IL6, IL8 and TNFα) and inducing the production of anti-inflammatory 
agents (such as IL-1 receptor antagonist). IL10 also suppresses nitric oxide release in 
lymphocytes [2]. Local administration of recombinant IL10 effectively reduces pro-
inflammatory cytokine activity in animal models of diseases such as sepsis, stroke, 
multiple sclerosis and chronic inflammatory disorders [3] [4] [5] [6]. 
Studies of inflammatory flare-up reactions in animal models have shown the 
applicability and viability of local gene therapy in arthritis [7]. Ideally, treatments for 
chronic inflammatory diseases should parallel the course of the disease itself, matching 
the varying pathological conditions and thereby avoiding undesirable secondary effects. 
An ideal vector system would therefore be disease-regulated, expressing high levels of 
anti-inflammatory agents during relapses and lower levels during remission phases of 
the disease. 
Several viral expression systems that respond to inflammatory stimuli in vivo have been 
devised [8]. The first was based on a two-component adenoviral expression system in 
which the promoter of complement factor 3 drives transcription of the HIV 
transactivator of transcription (Tat) [9]. However, the immunogenicity of Tat has been 
implicated in central nervous system disorders. Subsequently, van de Loo et al. [10] 
developed a hybrid inflammation-inducible adenoviral expression system, consisting of 
the human IL-6 promoter fused to the enhancer region of the human IL-1 promoter. The 
therapeutic efficacy of adenoviral systems is, however, compromised by the induction 
of an adenovirus-mediated immune response and by the rapid loss of transgene 
expression due to the episomal localization of the viral genomes. More recently, an 
inflammation-inducible expression system based on serotype 5 adeno-associated virus 
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has been developed by employing a chimeric promoter based on NF-kB binding sites 
[11]. However, although the non-pathogenicity of adeno-associated viruses makes them 
promising candidates for long term gene therapy, under some circumstances they too 
can cause an inflammatory response in the host [12-14]. A potentially more appropriate 
system for gene therapy in chronic inflammatory processes would be lentiviral vectors, 
since they can infect both dividing and quiescent cells, provide long-term expression, 
and display low immunogenicity [15]. 
Currently, the most frequently used promoters used for transgene expression are viral, 
but these strong promoters are usually silenced, and result in only transient expression 
in vivo. Moreover, even if high expression of the transgene were successful, the 
constant high levels of anti-inflammatory molecules might increase the risk of infection, 
as already observed with anti-TNF-α and anti-IL-1 treatment of patients with 
rheumatoid arthritis [16-19]. In addition, there might be an adaptive response to the 
constant high concentration of transgene protein, counteracting its therapeutic effect. 
Several vectors driven by drug-controlled promoters have been developed to achieve 
regulated transgene expression; however, this approach requires constant monitoring of 
the disease to achieve optimal efficacy, and this is further complicated by the 
unpredictable, relapsing course of the disease. 
TNF-α and IL-1 are early-induced pro-inflammatory cytokines that act locally on 
vascular endothelium to induce the expression of adhesion molecules, including 
selectins and ligands for leukocyte integrins, which participate in the capture and 
recruitment of blood cells [20]. The selectins are a family of three type-I cell surface 
glycoproteins (E-, L- and P-selectin) involved in chronic and acute inflammation. E-
selectin (ESEL) is rapidly and transiently expressed in response to inflammatory 
cytokines such as TNF-α and IL-1, and is not expressed under basal conditions except 
in skin microvessels [21]. The promoter of human ESEL has been used for in vitro gene 
delivery in recombinant retroviral and adenoviral vectors [22, 23] and for in vivo 
delivery in non-viral vectors [24-26]. Here we report the development of a lentiviral 
expression system based on the ESEL promoter (ESELp). We show that ESELp-driven 
transgene expression is induced in response to pro-inflammatory cytokines in cell 
culture, and is regulated in vivo during chronic paw inflammation. This long term 
expression system shows low basal activity during remission and high expression 
during the acute inflammatory response. The lentiviral vector system drives in vivo 
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expression of the anti-inflammatory cytokine IL-10 at levels sufficient to efficiently 
attenuate repetitive local acute inflammation episodes induced by zymosan injection. 
This attenuation is also observed when the lentiviral vector system is administered after 
zymosan injection. Therefore, this new expression system fulfills the requirements for a 
disease-regulated on/off system, suggesting potential use for auto-regulated treatment of 
chronic inflammatory diseases. 
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Results 
ESELp-driven transgene expression is efficiently activated by 
proinflammatory cytokines in lentivirus-transduced endothelial cells 
To assess the ability of lentivectors to efficiently transduce endothelial cells, we 
infected mouse or human primary endothelial cell cultures (MLEC and HUVEC) with a 
lentiviral vector (LV) encoding GFP under the control of the constitutive SFFV viral 
promoter (LV-SFFVp-GFP). In addition, we infected immortalized MLEC (iMLEC) 
[27]. GFP expression was analyzed after 48h, and the efficiency of transduction was 
close to 100% in all cases (Supplementary Figure S1). 
Since E-selectin is the earliest endothelium-specific adhesion molecule induced 
by pro-inflammatory cytokines, we tested whether the ESELp might be a useful tool for 
achieving targeted transgene expression at sites of inflammation. We generated a 
lentiviral vector encoding GFP under the control of ESELp (LV-ESELp-GFP; 
Supplementary Figure S2) and infected iMLEC and HUVEC. Treatment of infected 
cells with TNF-α strongly increased GFP expression in both cell types, paralleling the 
expression of endogenous ESEL (Figure 1a,b). In contrast, GFP expression from the 
constitutively active LV-SFFVp-GFP vector was not modified by TNF-α treatment 
(Supplementary Figure S3). The potent induction by TNF-α of endogenous ESEL in 
vitro is greatly enhanced by preincubation with the proangiogenic factor VEGF [28]. 
We therefore preincubated infected cells for 24 h with VEGF and then with TNF-α for 
different periods. As in the case of endogenous E-selectin, VEGF pretreatment 
potentiated TNFα-induced ESELp-driven expression of GFP; induction of GFP 
expression peaked at 6 h both in VEGF and in vehicle pretreated cells, and declined 
after 12h (Supplementary Figure 4a). 
As VSV-pseudotyped LVs have a broad host range, we tested the ESELp 
activity in non endothelial immortalized and primary cells susceptible to be infected 
after intraplantar administration by employing a lentivector containing the luciferase 
reporter gene under the control of the ESELp (LV-ESELp-Luc; Supplementary Figure 
S2). Treatment of infected cells with pro-inflammatory cytokines increased luciferase 
expression in all cell types assayed (Figure 1c-f). However, only in the case of 
stimulated LV-ESELp transduced endothelial cells the level of luciferase was similar to 
that observed in LV-SFFVp transduced cells (Figure 1c). In the rest of cell types we 
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found a low basal level of  luciferase expression and modest induction upon stimulation 
(Figure 4d-f). 
We next investigated whether LV-ESELp could be activated by an inflammatory 
milieu. Injection of mice with lipopolysaccharide (LPS) induces the release of pro-
inflammatory cytokines, resulting in activation of the endothelium and the expression of 
additional pro-inflammatory factors and cell-specific adhesion molecules that 
participate in the inflammatory response [27]. To test the effect of these inflammatory 
mediators on LV-ESELp, we transduced endothelial cells with LV-ESELp-Luc and 
treated these cells with culture supernatant from LPS-activated macrophages [29]. The 
cytokine-containing supernatant increased luciferase activity in iMLEC transduced with 
LV-ESELp-Luc but had no effect on cells transduced with LV-SFFVp-Luc 
(Supplementary Figure 4b). LV-ESELp-Luc driven luciferase activity was also 
increased by treatment with VEGF plus TNF-α, but direct treatment with LPS did not 
modify luciferase activity in endothelial cells driven by either SFFVp or ESELp (data 
not shown). 
 
ESELp-driven transgene expression is induced by proinflammatory 
cytokines in a mouse subcutaneous matrigel model 
The inducibility of LV-ESELp-Luc by inflammatory mediators was further investigated 
by subcutaneous matrigel experiments in mice. iMLEC were transduced with LV-
SFFVp-Luc or LV-ESELp-Luc, and, after 24 h, cells were embedded in VEGF-
containing matrigel and injected subcutaneously into syngenic mice. Forty-eight hours 
later, mice were treated with LPS (i.p.), and luciferase activity in matrigel plugs was 
monitored by in vivo optical bioluminescence imaging. LPS administration led to 
similar increases in serum IL-6 levels in all mice, but luciferase activity was increased 
only in LV-ESELp-Luc matrigel implants, thus confirming the selectivity of ESELp 
induction by inflammatory cytokines in vivo (Figure 2 and Supplementary Figure 
S5). 
 
ESELp-driven transgene expression is modulated by proinflammatory 
cytokines in a mouse model of chronic inflammation 
We next addressed the inducibility of the lentiviral vector system in a mouse model of 
rheumatoid arthritis, a disease characterized by chronic inflammation of the joints which 
leads to destruction of cartilage and bone. We used a zymosan-induced arthritis (ZIA) 
 8
model, in which intraplantar administration of zymosan, a glucan obtained from yeast 
cell wall, induces the secretion of inflammatory interleukins [30]. Intraplantar injection 
of zymosan causes pronounced, dose-dependent edema. This inflammatory response is 
time-dependent and can last up to 14 days following zymosan administration. LV-
SFFVp-Luc or LV-ESELp-Luc was injected subcutaneously into both hind paws one 
week before zymosan administration to allow sufficient time for integration of the 
vector genome. After one week the right paw was injected with zymosan and the left 
paw with physiological saline solution. Luciferase expression was monitored by 
imaging of luciferase bioluminescence every three-to-four days over the first two 
weeks, when the signal intensity started to decrease, with additional measurements after 
20 and 30 days. Compared with control paws, the inflamed paws showed a notable 
induction of ESELp-driven luciferase expression four days after zymosan injection, 
reaching a maximum after seven days and decreasing from this point (Figure 3a-c). In 
contrast, paws injected with SFFVp-Luc showed no differences in luciferase expression 
upon injection with zymosan (Figure 3a-c). Comparable progression of ZIA in LV-
SFFVp-Luc and LV-ESELp-Luc-injected paws was confirmed by measuring paw 
diameter (Figure 3d). In addition, inflammation was measured by bioluminescence 
after i.p. administration of luminol, which allows quantitative longitudinal monitoring 
of myeloperoxidase (MPO) system activity [31] (Figure 3e). LV injection by itself 
produced no inflammatory reaction that could contribute to ZIA, since luminol reactions 
were only observed in zymosan-treated paws. 
It has been demonstrated that the majority of transduced cells after lentivector foot pad 
administration are dendritic cells (90% CD11c positive cells) which can migrate to the 
draining lymph nodes and spleen [32]. To test whether locally infected cells were 
migrating and luciferase was expressed in these organs, lymph nodes, spleen and liver 
were extracted from LV-transduced animals 5 days after zymosan administration. Total 
tissue homogenates from these organs were employed to measure the luciferase activity. 
The results showed that only very low luciferase activity was detected in the popliteal 
lymph node draining the paw infected with the luciferase-bearing LV (Figure 3 f,g). 
Although we cannot rule out that LV particles may reach these and other organs, this 
result suggests that transgene expression remains restricted to the paw after zymosan 
injection. 
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To identify the uncharacterized 10% of transduced cells, we performed double 
immunostaining in cross-sections of paraffin-embedded transduced paws. Our 
preliminary data indicate that transgenes are expressed in transduced endothelial cells in 
vivo (data not shown); however further experiments would need to be performed to 
confirm these data and investigate whether other cell types are contributing to the 
overall transgene expression in vivo. 
 
ESELp-driven transgene expression in vivo responds to inflammation 
flare-ups 
An important aim in gene therapy is the development of expression systems which can 
be switched on and off on demand. Such vectors would allow cessation of transgene 
expression upon resolution of the pathological process, and its restoration should the 
disorder reactivate. We therefore wanted to determine whether our lentiviral ESELp-
driven expression system is modulated by the inflammatory conditions induced by 
zymosan. We monitored the inflamed paws after the first injection of zymosan by 
weekly measurement of the bioluminescence produced in response to i.p. administration 
of luminol. After one month, no detectable bioluminescence signal was generated in the 
paws, and correspondingly control and zymosan-injected paws showed no differences in 
ESELp-driven luciferase activity (day 30, Figure 4a). At this point, we reactivated the 
inflammation by administering a second zymosan injection to the same paw, and 
monitored SFFVp- and ESELp-controlled luciferase expression by bioluminiscence. 
The new inflammatory process again led to an increase in ESELp-driven transgene 
expression in the zymosan-injected paws, whereas no apparent changes were observed 
in paws infected with LV-SFFVp-Luc (Figure 4a,b and Supplementary Figure S7a). 
The acute inflammatory reaction induced by the second zymosan injection was similar 
in LV-SFFVp-Luc and LV-ESELp-Luc-infected mice, as estimated by paw diameter 
and luminol bioluminescence (Figure 4c and Supplementary Figure S7b). These data 
indicate that the ESELp-driven lentiviral expression system has the potential to 
selectively target inflammatory tissues and can be re-induced by acute inflammatory 
episodes. 
 
Comparative study of transgene expression under different inflammation-
inducible expression systems  
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As other viral expression systems that respond to inflammatory stimuli have been 
described, we decided to compare the transcriptional inducibility of ESELp with two 
other inflammation-inducible promoters: a NF-kB responsive promoter (NFkBp) and a 
hybrid promoter based on the human IL-6 promoter fused to the enhancer region of the 
human IL-1 promoter (IL1-IL6p) [10, 11]. After replacing ESELp with either NFkBp or 
IL1-IL6p and generating the corresponding luciferase-containing LVs, we employed 
them to transduce different cell lines. We found that LV-NFkBp displayed the highest 
luciferase activity in non endothelial cells (Figure 5a,b); however, in endothelial cells 
LV-ESELp and LV-NFkBp showed similar basal luciferase activity (Figure 5a,c). 
Upon stimulation, LV-ESELp was induced in all the cell types tested (Figure 6a-c), 
displaying the highest luciferase activity in endothelial cells (Figure 5c). In the case of 
LV-IL1-IL6p, it showed the highest induction in RAW cells after treatment with LPS, 
displaying luciferase units similar to those already published [10]. 
Next, we compared these inflammation-inducible systems in vivo. For this, LV-ESELp-
Luc, LV-NFkBp-Luc or LV-IL1-IL6p-Luc was injected subcutaneously into both hind 
paws and one week later the right paw was injected with zymosan and the left paw with 
physiological saline solution. Luciferase expression was monitored by imaging of 
luciferase bioluminescence four days after zymosan injection. As shown in Figure 5d, 
LV-NFkBp displayed very high luciferase basal activity that was further increased after 
zymosan injection. LV-IL1IL6p displayed the lowest luciferase activity and the modest 
induction observed has no statistical significance. Once again, LV-ESELp showed a low 
basal activity which was significantly increased after zymosan administration. 
 
ESELp-driven IL10 expression attenuates local acute inflammation in vivo 
Since IL-10 shows potential as an anti-arthritic agent which counteracts the actions of 
pro-inflammatory molecules, we used the inflammation-regulated LV-ESELp system to 
express this cytokine. Cells infected with LV driving expression of IL10 (LV-ESELp-
IL10) released this interleukin into the culture medium (Supplementary Table S1). To 
test the efficacy of lentiviral-driven IL10 expression in vivo, we injected LV-ESELp-
IL10 subcutaneously into the right hind paw and LV-ESELp-Luc into the left hind paw 
of the same animal, so that each mouse served as its own control. Another group of 
animals was similarly administered with LV-SFFVp-IL10 and LV-SFFVp-Luc. One 
week later, ZIA was induced in both hind paws, and MPO (luminol) and luciferase 
activities were monitored by imaging of bioluminescence every other day until 
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inflammation remission began (10 days). Compared with the luciferase-expressing 
inflamed paws, the IL10-expressing paws showed a notable reduction in MPO activity, 
by 90% and 70% three days after zymosan injection in the case of LV-SFFVp and LV-
ESELp, respectively (Figure 6a and Supplementary Figure S7). This was 
accompanied by corresponding reductions in paw swelling (Figure 6b).  
To test the reactivation of the system, we administered a second zymosan injection after 
remission of the first acute episode, and monitored luciferase and MPO activity by 
bioluminiscence. The second acute inflammatory episode was again attenuated in the 
IL-10-expressing paws (Figure 6c,d). The smaller attenuation observed correlated with 
the lower degree of inflammation (MPO activity) after a repeated zymosan 
administration (Figure 4). These results show that the anti-inflammatory effect obtained 
by low and transient level of IL10 expressed under LV-ESELp was similar to that 
observed after the high and constant level of IL10 released by the LV-SFFVp. 
Therefore, the expression of IL10 under the LV-ESELp would avoid the side effects 
associated with a prolonged release of IL10. 
Locally released IL-10 might reach the blood stream, raising its serum level and 
therefore increasing the risk of infection. To test this, we measured IL-10 paw and 
serum levels in the two animal groups 5 days after the first zymosan bout. We found 
that both LV-SFFVp-IL10 and LV-ESELp-IL10 increased the local amount of IL-10 
(Figure 6e); however, only the injection of LV-SFFVp-IL10 significantly raised IL-10 
serum level which might cause immunosuppression and put the animals at risk of 
opportunistic infections (Figure 6f). Therefore, these results suggest that LV-ESELp-
IL10 local administration does not increase susceptibility to infections. 
 
As the local environment in the animal paw is different after zymosan injection, we 
wondered whether our lentiviral system was also effective when it was administered 
after zymosan injection. We injected LV-ESELp-IL10 subcutaneously into the right 
hind paw and LV-ESELp-Luc into the left hind paw of the same animal one day after 
zymosan administration. Another group of animals was similarly administered with LV-
SFFVp-IL10 and LV-SFFVp-Luc. We monitored luciferase activity and found the peak 
at day 7 after zymosan injection (Figure 7a). At that time there was a clear swelling 
reduction in the IL10 expressing paws in both groups which was maintained at least for 
two more days (Figure 7b). These results showed that LV-ESELp also works when it is 
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administered after the initiation of inflammation; therefore, it might be useful as a 
therapeutic tool after detecting a new inflammatory episode. 
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Discussion 
The inflammatory response is precisely controlled by the expression of cytokines whose 
local levels are directly related to the severity of the process. A major challenge in the 
treatment of chronic inflammatory diseases is the development of an expression system 
that is tightly regulated by the variable levels of these cytokines. This study describes a 
long-term lentiviral expression system based on the E-selectin promoter, and which is 
locally induced by inflammatory stimuli in direct correlation with the intensity and 
duration of the inflammatory response. 
Studies in animal models have shown that gene therapy is an alternative for the 
local treatment of chronic inflammatory diseases. One of the critical factors in gene 
transfer is the type of vector employed. Non-viral vectors commonly yield low gene 
transfer efficiency [33, 34]. Among the viral vectors, adenoviruses are the most widely 
used, but they are poor candidates for the treatment of chronic inflammatory diseases 
because of the immune response associated with their application and the rapid loss of 
transgene expression due to lack of persistence of the viral genomes [35, 36]. Adeno-
associated viruses (AAV) have emerged as a very promising alternative, since although 
AAV vectors have limited cargo capacity, they stably transduce host cells and show low 
immunogenicity. However, recent studies have reported an inflammatory response after 
AAV application [12-14]. In addition, technical limitations limit the scalability of AAV 
vectors, making it difficult to produce adequate viral titers [37-39]. As an alternative, 
lentivirus-derived expression systems have been employed in animal models of 
neuroinflammation [40]. Lentivectors not only infect dividing and quiescent cells, but 
they also provide long-term expression and show low immunogenicity. In addition, the 
biosafety profile of lentiviral vectors has been improved significantly by minimizing the 
regions of homology between vector and helper sequences (split configuration), and by 
using heterologous promoters [41]. Furthermore, the use of vesicular stomatitis virus 
glycoprotein (VSV-G) confers efficient transduction in a wide range of cell types from 
many species, and allows high titers of the lentiviral particles for clinical applications 
[42, 43]. Our study suggests that lentivectors may also be a valuable alternative in the 
treatment of chronic inflammatory diseases. 
Several inflammation-inducible systems have been described recently, all of 
which are based on chimeric promoters. The precise in vivo regulation of these tailored 
promoters is still unknown. Our expression system is based on the proximal promoter 
region that controls the expression of the E-selectin gene. This gene is particularly 
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attractive as it is induced early and transiently upon inflammation and its promoter 
region contains the binding sites for transcription factors induced by the early-induced 
pro-inflammatory cytokines TNF-α and IL-1. Compared to other described expression 
systems, the ESELp-based system shows the highest transcriptional activity in 
endothelial cells. In addition, our expression system is highly induced in endothelial 
cells by the early-induced pro-inflammatory cytokines TNF-α and IL-1. These results 
are important as activated endothelium plays an important role in inflammation 
initiation. We tested our expression system in an experimental model of chronic 
inflammation by administering repeated local injections of zymosan. ESELp-driven 
transgene expression is rapidly induced after zymosan administration, coinciding with 
the peak of inflammation 7 days after the first treatment, and is maintained until 
inflammation recedes. Compared to other inflammation-inducible systems, the ESELp-
based is characterized by a low basal activity that after zymosan administration 
increased to levels similar to those observed with a strong viral promoter. The other 
expression systems analyzed showed either very high basal activity (NFkB-based 
system) or very low inducibility after inflammation (IL1-IL6p-based system). Our 
results show that ESELp-dependent transgene expression increases several fold, 
correlating with the severity of inflammation in the animal system tested. Future 
experiments will enable more detailed comparison of how these expression systems 
perform in gene transfer models. 
Since chronic inflammatory diseases are characterized by flare-ups and 
remission phases, it was important to test whether the promoter was silenced in vivo and 
whether transgene expression could be re-induced after a second zymosan boost. 
Transgene expression again correlated with inflammatory status after a second zymosan 
boost, showing no evidence of promoter silencing. We therefore consider the ESELp a 
valuable tool for the development of gene expression systems for the treatment of 
chronic inflammatory diseases. The use of ESELp-based gene delivery systems to 
selectively express anti-inflammatory agents in arthritis-affected joints might eliminate 
some of the problems of tolerability and compliance associated with systemic drug 
therapies. 
One important issue in locally applied gene therapy is to study the putative migration of 
transduced cells in vivo. In this regard, it has been demonstrated that LV injection into 
the mouse footpad transduces DCs which are able to migrate to the draining lymph 
nodes and spleen [32]. However, we only detected residual luciferase activity in the 
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popliteal lymph nodes draining the infected paw suggesting that transduced DCs remain 
in the local inflammatory focus (Figure 3f,g). This is in agreement with previously 
published results showing that IL-10 transgene expression modulates DC maturation 
[44, 45]. The authors observed that DCs transduced with adenoviral vectors expressing 
IL-10 maintained an immature state characterized by low MHC class II, CD86, and IL-
12 expression. The immaturity might affect to their migratory ability which would 
support our in vivo results. Further experiments should be performed to further 
characterize the impact of IL-10 expression on DC migration in vivo. 
The occurrence of unpredictable relapses complicates the treatment of chronic 
inflammatory diseases. Rheumatoid arthritis (RA), the most frequent inflammatory 
rheumatic disorder, is a paradigm of chronic inflammatory diseases characterized by an 
imbalance of pro- and anti-inflammatory molecules. Although systemic administration 
of anti-inflammatory agents is beneficial to patients with chronic RA, these treatments 
are limited by loss of efficiency and relapse after treatment cessation. There are also 
significant side effects associated with a prolonged systemic imbalance of the natural 
inflammatory response [46, 47]. Viral vectors are promising candidates for gene therapy 
for local treatment of RA, and several clinical trials are underway [48]. However, there 
is still a need to develop new therapeutic approaches that provide prolonged remission 
from disease with limited side effects by targeting anti-inflammatory mediators to the 
diseased joints. The use of disease-regulated promoters to drive transgene expression 
might provide therapeutic levels of the anti-inflammatory agent exclusively during flare 
ups. In addition, administration of virus directly into arthritic joints should avoid the 
side effects associated with systemic administration and increase the site-specific effects 
of the therapeutic agent. 
It has been shown that local administration of recombinant IL10 effectively reduces pro-
inflammatory cytokine activity in several animal models of human diseases; however, 
constant high levels of anti-inflammatory molecules might increase the risk of infection, 
therefore prolonged administration of IL10 is limited by associated side effects. Our 
study demonstrates that activation of the LV-ESELp lentiviral expression system is 
regulated by the local level of inflammation. Moreover, the LV-ESELp system drives 
inflammation-regulated IL10 expression at levels sufficient to reduce acute 
inflammation induced by zymosan with no effect in the IL10 serum levels. Although the 
LV-ESELp system releases considerably lower local concentrations of IL-10 than the 
constitutive expression vector LV-SFFVp, it is noteworthy that regulated IL10 
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expression is as effective as constant expression in reducing inflammation in vivo. 
Furthermore, the inducible system is switched off during remission of the inflammation, 
thus avoiding the risks associated with a sustained release of IL-10. Altogether, these 
results suggest that local administration of LV-ESELp-IL10 should not increase animal 
susceptibility to opportunistic infections. As expected, the levels of inflammation and 
transgene induction are lower after the second bout than observed at disease onset. This 
endogenously-regulated system for the local expression of anti-inflammatory molecules 
provides a potential new approach for the local treatment of chronic inflammatory 
diseases. 
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Materials and Methods 
Plasmid constructs 
The human E-selectin promoter (-940;+40) (ESELp) was amplified from human 
genomic DNA by PCR. The PCR product was cloned into the pHRSIN HIV-derived 
transfer vector to replace the ubiquitously expressed spleen forming Focus virus 
promoter, SFFVp. Firefly luciferase cDNA was PCR amplified from a commercially 
available plasmid (pGL3 Basic). 
The NFkB chimeric promoter (NFkBp) was generated by annealing sense and antisense 
oligonucleotides and direct cloning into pBlueScript in the following order: HindIII-
EcoRI minimal CMV promoter (sense 5’ 
AGCTTGTAGGCGTGTACGGTGGAGGTCTATATAAGCAGAGCTCG 3’; 
antisense 5’ AATTCGAGCTCTGCTTATATAGACCTCCACCGTACACGCCTACA 
3’), XhoI-3xNFkB-HindIII (sense 5’ 
TCGAGGGACTTTCCACAAGGGGACTTTCCACAAGGGGACTTTCC 3’; antisense 
5’ AGCTGGAAAGTCCCCTTGTGGAAAGTCCCCTTGTGGAAAGTCCC 3’) and   
KpnI-MluI-3xNFkB-XhoI (sense 5’ 
CACGCGTGGGACTTTCCACAAGGGGACTTTCCACAAGGGGACTTTCC 3’; 
antisense 5’ 
TCGAGGAAAGTCCCCTTGTGGAAAGTCCCCTTGTGGAAAGTCCCACGCGTG
GTAC 3’). The IL1-IL6 hybrid promoter (IL1-IL6p) was generated by cloning the PCR 
products containing the human IL1 enhancer (-3690;-2720) and the human IL6 
promoter (-172;+12) into pBlueScript. The PCR primers employed were MluI-IL1-fwd 
(5’ CCACGCGTGATCCAAGAGGGAGAAGAAGC 3’), XbaI-IL1-rv (5’ 
GGTCTAGACTGATGCTTTCGCTCGAGGG 3’), IL6-fwd (5’ 
GGCTTAGCGCTAGCCTCAATGAC 3’) and BamHI-IL6-rv (5’ 
GGGGATCCGAGACTCTAATATTGAGACTCATGGG 3’). The ESELp sequence 
was removed from pHRSIN-ESELp-Luc-IRES-GFP by MluI and BamHI digestion and 
replaced by either NFkBp or IL1-IL6p. 
The IL-10 coding sequence was amplified by PCR using cDNA generated from total 
RNA extracted from LPS-treated RAW cells. The PCR products were directly cloned 
into the SIN-BX plasmid to generate the bicistronic cassettes. The luciferase-IRES-GFP 
and IL10-IRES-GFP inserts were cloned into the pHRSIN-SFFVp and pHRSIN-ESELp 
transfer plasmids. The sequences of all plasmids were confirmed and are available in 
our lab websites (http://www.rodriguezlab.com or http://www.lablife.org/labs/947). 
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Lentivirus production and titration 
HEK-293 cells were transiently transfected by the calcium phosphate method. For viral 
particle production, the indicated pHRSIN transfer plasmid was co-transfected with two 
helper plasmids (8.9 and pMD2-G). Supernatants were collected 48 h after transient 
transfection and cell debris was removed by centrifugation (10 min, 740xg, 4ºC). Viral 
particles were concentrated by ultracentrifugation in a swing bucket rotor for 2 h at 
121,986xg, 4ºC (Ultraclear Tubes, SW28 rotor and Optima L-100 XP Ultracentrifuge, 
Beckman). After removal of the supernatant, viral particles were resuspended in PBS 
and stored at -80ºC until use. 
Total viral content was determined by qPCR [49]. The concentration of transducing 
units (TU) was calculated by infecting 50,000 Jurkat cells (in a p96 plate), with 1 μl, 0.1 
μl and 0.01 μl (duplicates) of concentrated viral supernatant. After 12 h, viruses were 
removed and cells were suspended in PBS and analyzed by flow cytometry (FACS 
Canto HTS, Beckton Dickinson); the number of infective particles/μl was calculated 
from the percentage of GFP positive cells. 
 
Cell culture, transient transfection and transduction 
HEK-293 (ATCC #CRL-1573), RAW 264.7 (ATCC #TIB-71) cells were grown in 
Dulbecco’s modified Eagle medium (DMEM, Bio-Whittaker, Lonza) supplemented 
with 10% fetal bovine serum (FBS, Sigma) and L-glutamine plus antibiotics (100 
units/ml penicillin and 100 μg/ml streptomycin). Jurkat cells were cultured in RPMI 
medium (RPMI, Bio-Whittaker, Lonza) containing 10% FBS and L-glutamine plus 
antibiotics. Mouse embryonic fibroblasts (MEFs) were derived from wildtype mice, 
immortalized with SV40 T large antigen using standard protocols (iMEFs), and grown 
in DMEM supplemented with 10% FBS plus antibiotics. Elicited peritoneal 
macrophages were obtained from male mice 4 days after intraperitoneal administration 
of 1 ml of 10% thioglycolate broth. Peritoneal macrophages were seeded at densities of 
0.5-1.0×106 cells in 24-multiwell plates in RPMI supplemented with 10% FBS and 
antibiotics for 12h and transduced. Mouse GM-CSF bone marrow-derived dendritic 
cells (DCs) were generated using GM-CSF-containing media by standard protocols. 
DCs cultured in the presence of GM-CSF were transduced at day 5 of culture. Primary 
cultures of human umbilical vein endothelial cells (HUVEC) and mouse lung 
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endothelial cells (MLEC) were isolated and maintained as described [50]. Immortalized 
MLEC (iMLEC) were grown in DMEM F-12 (Bio-Whittaker, Lonza) supplemented 
with 10% FBS, L-glutamine plus antibiotics (100 units/ml penicillin and 100 μg/ml 
streptomycin), and 50 μg/ml ECGF [27]. Cells were transduced for 5h at the indicated 
MOI, washed with PBS and serum-deprived for 12 h prior to stimulation with the 
indicated reagents. After stimulation, cells were trypsinized and harvested for further 
analysis. 
 
Flow cytometry, ELISA and luciferase assay 
GFP expression was analyzed by flow cytometry (FACScanto, BD) of harvested cells 
washed with PBS. For footpad cytokine extraction, each one was cut into small pieces 
in 0.2 ml RPMI with 10% FBS and were incubated for 45 min at 37°C to allow cytokine 
release. Cytokine-containing media were collected and centrifuged at 2,000xg for 20 
min. Footpad or cell culture supernatants were collected for cytokine detection by 
employing commercial ELISA kits (Quantikine immune assays; R&D systems) and 
measured in a Benchmark Plus microplate spectrophotometer (BIORAD). To determine 
luciferase activity, transduced cells were collected after stimulation, washed with PBS, 
lysed, and analyzed in an AutoLumat LB953 luminometer (Berthold Technologies). 
Results are expressed in relative light units (RLU). For tissue luciferase assays, 1ml of 
Reporter Lysis buffer was added to 100mg of each sample and homogenized at 4ºC 
using a tissue grinder. Tissue homogenates were centrifuged for 10 min at 12,800xg at 
4ºC. Supernatants were saved and employed for luciferase (20μl) and protein 
quantification (Bradford, BIORAD). Reporter gene expression is shown as RLU per μg 
of protein. 
 
Animals 
4-week-old male and female C57/BL6 mice (Charles River) were fed lab chow and kept 
on a 12 h light/dark cycle. The animals were cared for according to the CNIC Animal 
Facility guidelines for the care and use of laboratory animals. 
 
In vivo optical bioluminescence imaging 
Bioluminescent imaging analysis was conducted with the IVIS 200 in vivo imaging 
system (Caliper). Mice were i.p. injected with 150 mg/kg firefly luciferin (Promega) 15 
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min before imaging and anesthetized with isoflurane during the procedure. Photons 
emitted from live mice were acquired as photons per s/cm2 per steradian, using Living 
Imaging 3.0 (Caliper). For photon quantification, a region of interest (ROI) was 
manually selected and kept constant within each experiment.  
 
In vivo matrigel plug assay 
iMLEC transduced with lentiviral particles containing luciferase cDNA were embedded 
in matrigel (Sigma) which was implanted subcutaneously in the chest of mice. After 24 
h, lipopolyssaccharide (40mg/ml LPS from E. coli; Sigma) was intraperitoneally 
injected and blood samples were obtained 4-6 h later to determine serum cytokine levels 
(IL-6) by ELISA. Bioluminiscence due to luciferase activity was monitored (see above) 
24, 48 and 72 h after LPS treatment. 
 
Zymosan Induced Arthritis (ZIA) animal model 
Viral particles (2x107 TU) were injected into each hind paw of the mouse. After one 
week, the left paw was injected with saline solution (30 μl) and arthritis was induced in 
the right paw by intraplantar administration of 180 μg zymosan [30]. Luciferase 
expression was monitored over one month using the IVIS 200 system (Caliper). 
Inflammation was determined by paw diameter and by monitoring the luminiscence 
after i.p. administration of luminol (Sigma) [31]. 
 
Statistical analysis 
Data were analyzed for statistical significance using GraphPad Prism (version 5.01). 
Data shown in figure 2 were analyzed by one-way ANOVA followed by Newman-
Keuls multiple comparison test. Data from ZIA experiments were analyzed by t test. 
Statistical significance was assigned at p<0.05. SEM, Standard Error of the Mean; SD, 
Standard Deviation. 
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Supplementary Material 
 
Supplementary Figures 
Figure S1. Endothelial cells are efficiently infected by lentivectors in vitro. (a) Plasmid 
map of the transfer lentivector employed, which expresses GFP under the control of a 
strong viral promoter SFFVp (cPPT=central polypurine track; RRE=Rev-responsve 
element; GFP=green fluorescence protein; IRES=internal ribosome entry sequence; 
SFFV=spleen focus forming virus; WPRE=woodchuck post-transcriptional element). 
(b) HUVEC (top), MLEC (middle) and immortalized MLEC (bottom) were infected 
with 1200 TU of LV-SFFVp-GFP, and after 48 h GFP expression was assessed by 
fluorescence microscopy (left panels) and flow cytometry (right panels). 
 
Figure S2. Lentiviral vectors containing the human E-selectin promoter sequence. (a,b) 
Plasmid map of the HIV-derived lentiviral vectors containing the human ESEL 
promoter (ESELp) which controls the expression of either (a) GFP (LV-ESELp-GFP) or 
(b) the luciferase-IRES-GFP bicistronic cassette (LV-ESELp-Luc). (c) Organization of 
the regulatory elements found in the E-selectin promoter. Predicted transcription factor 
binding sites were identified by MatInspector and Matrix Family Library (version 8.2) 
from Genomatix (www.genomatix.de). The fully characterized proximal region (first 
160 base pairs) is indicated (box). 
 
Figure S3. Constitutive GFP expression driven by the SFFVp viral promoter is not 
affected by TNF-treatment. Flow cytometry histograms showing constitutive expression 
of GFP with (right) and without (left) TNFα treatment in HUVEC transduced with 
lentivectors encoding SFFVp-GFP. 
 
Figure S4. ESELp-based lentiviral system is induced by an inflammatory milieu in 
endothelial cells. (a) HUVEC were infected with LV-ESELp-GFP and either left 
untreated or preincubated with 50 ng/ml VEGF for 24 h. Cells were then incubated with 
30 ng/ml TNF-α for a further 6, 12 or 24 h, and GFP expression was analyzed by flow 
cytometry. The graph shows mean GFP fluorescence intensity in each condition from a 
representative experiment of three performed. (b) iMLEC were infected with the 
indicated LUC-containing lentiviral vectors. Twenty four hours after infection, cells 
were treated as in (a) (gray bars; V+T) or with the supernatant obtained from LPS-
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treated RAW macrophages (black bars; SN). Luciferase activity was measured after 30 
h. The graph shows relative light units (RLU) for each condition. 
 
Figure S5. In vivo optical bioluminescence images of luciferase activity from a 
representative experiment of the ESELp-driven transgene expression induced by 
proinflammatory cytokines in a mouse subcutaneous matrigel model. 
 
Figure S6. Inflammation induced by the second zymosan administration. 
Representative bioluminescence images of (a) Luciferase and (b) luminol activities of 
paws infected with the indicated lentiviral vectors after the second inflammatory insult. 
 
Figure S7. IL-10 release from the SFFVp lentiviral system in vivo. One group of mice 
received an intra-articular injection of LV-SFFVp-Luc in one hind paw and LV-SFFVp-
IL10 in the other. After one week, mice received intra-articular injections of 180 μg 
zymosan in both hind paws. MPO activity was measured by bioluminescence at 
different times after zymosan injection, and the percentage of relative MPO activity was 
calculated; 100%=MPO activity in paws injected with LV-ESELp-Luc or LV-SFFVp-
Luc (*p<0.05 and ***p<0.001; n>5). 
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Supplementary Tables 
Table S1. IL10 release by LV-transduced cells. 
Cell LV Stimuli IL-10(pg/mL) 
HEK SFFVp-IL10 - 48,632.6+ 4,493.7
HUVEC ESELp-IL10 
-          1.4+ 0.7 
+        29.9+13.4 
Cells were transduced with the indicated lentiviral  
construct and stimulated with VEGF (24h) plus TNFα (6h). 
IL10 in culture supernatants was measured by ELISA. 
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Figure legends 
 
Figure 1. Inducibility of the ESELp-based lentiviral system in vitro. (a) HUVEC 
were infected with the LV-ESELp-GFP and left untreated (left) or incubated with 30 
ng/ml TNF-α (right) for 6 h. Flow cytometry histograms show the expression of 
endogenous E-selectin (top panels) and GFP (bottom panels). (b) LV-ESELp-GFP-
infected iMLEC were treated as in (a). Histograms show the fluorescence intensity of 
untreated cells (gray line) and TNF-treated cells (filled). (c,d) Immortalized and (e,f) 
primary cells were transduced for 5h with either LV-SFFVp or LV-ESELp, serum-
starved for 12h and stimulated with the indicated cytokines for 6h. The MOI employed 
was 5 for iMLEC and iMEF, 50 for peritoneal macrophages and 100 for bone-marrow 
derived dendritic cells. Three experiments were performed and one representative is 
shown (mean +SEM; n=3). *p<0.05 and ***p<0.001 vs. untreated cells. RLU, Relative 
Light Units. 
 
Figure 2. Proinflammatory cytokines induce the ESELp-based lentiviral system in 
vivo. Mice were injected subcutaneously with matrigel containing MLEC infected with 
either LV-SFFVp-GFP or LV-ESELp-GFP, and were subsequently injected (i.p.) as 
indicated with 40 mg/kg LPS. (a) Graph showing serum IL6 levels (mean+SD) from a 
representative experiment (n=9). (b) Scatter plots showing in vivo luciferase activity 
(flux) of mice from a representative experiment (ESELp: p=0.0090; n=9). (c). Graph 
showing in vivo luciferase activity (flux) as fold induction of LPS-treated vs. control 
mice (mean+ SD of three independent experiments;***p<0.001 vs. untreated mice). 
 
Figure 3. The ESELp-based lentivector drives local transgene expression at 
inflammatory sites. Mice received an intraplantar injection of either LV-SFFVp-Luc or 
LV-ESELp-Luc in both hind paws. After one week, mice received intraplantar 
injections of 180 μg zymosan in the right paw and saline solution in the left paw (as a 
negative control for inflammation). In vivo luciferase activity was determined by 
bioluminescence at different times after zymosan injection. (a) Fold induction of in vivo 
luciferase activity (flux) in zymosan- and saline-injected paws at the indicated times. (b) 
Scatter plot showing in vivo luciferase activity (flux) of control and ZIA-treated paws at 
day 7 (p<0.0016; n≥8). (c) Representative bioluminescence images of paws infected 
with the indicated vectors and treated with saline (C) or zymosan (ZIA) for 7 days. (d) 
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Graph showing the diameters (mm) of mouse hind paws infected with the indicated 
vectors and treated with saline (control) or zymosan (ZIA) for 7 days (mean+SEM; 
n≥8). **p<0.01 and ***p<0.001. (f,g) Luciferase activity detected in tissues from mice 
locally transduced with the indicated LV. Total tissue homogenates from liver, spleen, 
and the indicated lymph nodes were employed to measure luciferase activity (n=4), 
expressed as RLU (Relative Light Units) per microgram of protein (μg). 
 
Figure 4. Expression of the ESELp-based lentiviral system is regulated by the level 
of inflammation in vivo. (a) One month after the first zymosan injection, when the 
inflammation had receded, hind paws were re-injected with saline or 180 μg zymosan to 
reactivate inflammation. The graph shows fold induction of in vivo luciferase activity 
measured by bioluminescence in zymosan and saline re-injected paws of mice at the 
indicated times. (b) Scatter plot showing in vivo luciferase activity (flux) of control and 
ZIA-treated paws 7 days after the second zymosan boost (p=0.0027; n=7). (c) The graph 
shows the diameters (mean+SEM; n≥8) of mouse hind paws infected with the indicated 
vectors, measured 7 days after the second treatment with saline (control) or zymosan 
(ZIA). **p<0.01 and ***p<0.001. 
 
Figure 5. Comparative study of different inflammation-regulated systems. The 
ESELp-based system was compared with two other inflammation-inducible systems, 
the chimeric NFkB promoter (NFkBp) and the human IL1-IL6 hybrid promoter (IL1-
IL6p), (a-c) in cell cultures and (d) in vivo. (a-c) The indicated lentivector (LV) was 
employed to transduce (a) iMEF (MOI=5), (b) RAW (MOI=10) and (c) iMLEC 
(MOI=5) for 5h. After serum starvation, cells were incubated with (a,c) TNF 
(100ng/ml) plus IL1 (10ng/ml) for 6h or (b) with LPS (2μg/ml) for 24h. Three 
experiments were performed and one representative is shown (mean +SEM; n=3). 
Numbers indicate the fold induction (mean+SD; n=3). (d) Mice received an intraplantar 
injection of either LV-ESELp, LV-NFkBp-Luc or LV-IL1-IL6p-Luc in both hind paws. 
After one week, mice received intraplantar injections of zymosan (180 μg) in the right 
paw and saline solution in the left paw (C=control). In vivo luciferase activity was 
determined by bioluminescence after zymosan injection. Scatter plot shows in vivo 
luciferase activity (flux) of control and ZIA-treated paws at day 5 (n=5). *p<0.05, 
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**p<0.01 and ***p<0.001 vs. untreated cells or control hind paw; ns=not significant p 
value. 
 
Figure 6. IL-10 release from the ESELp lentiviral system attenuates zymosan-
induced inflammation. One group of mice received an intraplantar injection of LV-
ESELp-Luc in the left hind paw and LV-ESELp-IL10 in the right one. A second group 
received similar intraplantar injections of LV-SFFVp-Luc and LV-SFFVp-IL10. After 
one week, mice received intraplantar injections of 180 μg zymosan in both hind paws. 
(a) MPO activity was measured by bioluminescence at different times after zymosan 
injection, and the percentage of relative MPO activity was calculated; 100%=MPO 
activity in paws injected with LV-ESELp-Luc or LV-SFFVp-Luc (*p<0.05 and 
**p<0.01; n>5). (b) Paw diameters measured 3 days after the first zymosan injection 
(*p<0.05; n>5). (c) After remission of the first acute inflammation, hind paws were re-
injected with zymosan (180 μg per paw) to reactivate inflammation, and MPO activity 
was measured by bioluminescence at different times (n=4). (d) The scatter plot shows in 
vivo MPO activity (flux) of ZIA-treated paws 6 days after the second bout. (e,f) IL10 
level present in (e) footpad supernatant and (f) serum from the indicated mice 5 days 
after the first zymosan bout was measured by ELISA (mean+SEM; n>4). *p<0.05 and 
***p<0.001 vs. control; ns=not significant p value. 
 
Figure 7. Therapeutic effect of ESELp-IL10 local administration. Mice received 
intraplantar injections of 180 μg zymosan in both hind paws. The next day, one group of 
mice received an intraplantar injection of LV-ESELp-Luc in the left hind paw and LV-
ESELp-IL10 in the right one. A second group received similar intraplantar injections of 
LV-SFFVp-Luc and LV-SFFVp-IL10. (a) In vivo luciferase activity was determined by 
bioluminescence after zymosan injection in both animal groups. (b) Paw diameters 
measured (top) 7 and (bottom) 9 days after the zymosan injection. The graph shows the 
diameters (mean+SEM; n=5) of mouse hind paws infected with the indicated vectors. 
*p<0.05 and **p<0.01 vs. control. 
 
 
 







